2-Pyrrolidone

2-Pyrrolidone

SCHEMBL867329

C=C(C)C(=O)OCCN(C)C.O=C1CCCN1

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OR51E2 Q9H255 1/20 0.42
THRB P10828 1/20 0.37
FKBP5 Q13451 1/20 0.37
CRBN Q96SW2 1/20 0.37
CHRM2 P08172 2/20 0.37
CHRM1 P11229 2/20 0.37
CHRM3 P20309 2/20 0.37
CHRM4 P08173 1/20 0.37
CHRM5 P08912 1/20 0.37
CHRNB2 P17787 1/20 0.37
CHRNA4 P43681 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
TSHR P16473 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
PARP1 P09874 4/20 0.34
BCHE P06276 1/20 0.33
PHLPP2 Q6ZVD8 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Caprolactam SCHEMBL6408803 0.95 FKBP5 (0.42) OR51E2THRBFKBP5CRBNCHRM2
Sulfuric Acid Dimethyl Ester SCHEMBL27866743 0.92 OR51E2 (0.35) OR51E2THRBFKBP5CRBNCHRM2
2-Pyrrolidone SCHEMBL27469715 0.86 OR51E2 (0.40) OR51E2THRBFKBP5CRBNCHRM2
2-Pyrrolidone SCHEMBL28304483 0.84 OR51E2 (0.46) OR51E2THRBFKBP5CRBNTSHR
2-Pyrrolidone SCHEMBL17241782 0.84 OR51E2 (0.46) OR51E2THRBFKBP5CRBNTSHR
2-Pyrrolidone SCHEMBL8133376 0.82 OR51E2 (0.47) OR51E2THRBFKBP5CRBNTSHR
2-Pyrrolidone SCHEMBL27468084 0.82 OR51E2 (0.41) OR51E2THRBFKBP5CRBNCHRM2
2-Pyrrolidone SCHEMBL8168482 0.82 TSHR (0.55) OR51E2THRBFKBP5CRBNL3MBTL1
Caprolactam SCHEMBL5610881 0.82 FKBP5 (0.40) OR51E2THRBFKBP5CRBNCHRM2
2-Pyrrolidone SCHEMBL28270057 0.80 OR51E2 (0.44) OR51E2THRBFKBP5CRBNTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 404 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4384310-A1 DEGRADABLE DELIVERY PARTICLES BASED FROM AMINE CONTAINING NATURAL MATERIALS Encapsys, LLC (US) 2024-06-19 EP claimed
EP-3596192-B1 BENEFIT AGENT CONTAINING DELIVERY PARTICLE SLURRIES PROCTER & GAMBLE (US) 2024-05-15 EP claimed
US-20240147990-A1 Delivery Particles Based On Amine-Thiol-Ene Conjugates and Derivatives ENCAPSYS, LLC (US) 2024-05-09 US claimed
WO-2024086501-A1 DELIVERY PARTICLES BASED ON AMINE-THIOL-ENE CONJUGATES AND DERIVATIVES ENCAPSYS, LLC (US) 2024-04-25 WO claimed
CN-117813153-A Degradable delivery particles based on amine-containing natural materials 恩盖普有限公司 2024-04-02 CN claimed
US-20240002745-A1 BIODEGRADABLE DELIVERY PARTICLES ENCAPSYS, LLC (US) 2024-01-04 US claimed
US-20240000073-A1 BIODEGRADABLE DELIVERY PARTICLES ENCAPSYS, LLC (US) 2024-01-04 US claimed
US-20230313084-A1 BENEFIT AGENT CONTAINING DELIVERY PARTICLE PROCTER & GAMBLE (US) 2023-10-05 US claimed
EP-4247896-A1 BIODEGRADABLE DELIVERY PARTICLES Encapsys, LLC (US) 2023-09-27 EP claimed
EP-4247162-A1 BIODEGRADABLE DELIVERY PARTICLES Encapsys, LLC (US) 2023-09-27 EP claimed
US-8765659-B2 Cationic polymer stabilized microcapsule composition THE PROCTER & GAMBLE COMPANY (US) 2014-07-01 US claimed
EP-2674477-A1 Cationic polymer stabilized microcapsule composition The Procter and Gamble Company (US) 2013-12-18 EP claimed
US-20110245141-A1 CATIONIC POLYMER STABILIZED MICROCAPSULE COMPOSITION THE PROCTER & GAMBLE COMPANY 2011-10-06 US claimed
US-7799752-B2 Compositions comprising encapsulated material QUEST INTERNATIONAL SERVICES B.V. (NL) 2010-09-21 US claimed
EP-2046935-A2 CATIONIC POLYMER STABILIZED MICROCAPSULE COMPOSITION Colgate-Palmolive Company (US) 2009-04-15 EP claimed
CN-101212957-A Pharmaceutical sustained-release composition and preparation method thereof PANACEA BIOTEC LTD (IN) 2008-07-02 CN claimed
WO-2008005693-A2 CATIONIC POLYMER STABILIZED MICROCAPSULE COMPOSITION COLGATE-PALMOLIVE COMPANY (US) 2008-01-10 WO claimed
CN-1518590-A Process for preparation of water-soluble particles of saldimine-type manganese complexes �������⻯ѧƷ�ع����޹�˾ 2004-08-04 CN claimed
EP-1354025-A1 PROCESS FOR THE PREPARATION OF WATER-SOLUBLE GRANULES OR PARTICLES OF SALDIMINE-TYPE MANGANESE COMPLEXES Ciba SC Holding AG (CH) 2003-10-22 EP claimed
WO-2002059245-A1 PROCESS FOR THE PREPARATION OF WATER-SOLUBLE GRANULES OR PARTICLES OF SALDIMINE-TYPE MANGANESE COMPLEXES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2002-08-01 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240000073-A1 BIODEGRADABLE DELIVERY PARTICLES VEGFA, FIBP, HDLBP OR51E2 3842/4885THRB 1561/4885FKBP5 1835/4885
US-20240147990-A1 Delivery Particles Based On Amine-Thiol-Ene Conjugates and Derivatives ACR, MMAB, UBE3C OR51E2 20/4885THRB 1780/4885FKBP5 1643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.